Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and seroton(2A) receptor binding
Autore:
Wihlback, AC; Sundstrom-Poromaa, I; Allard, P; Mjorndal, T; Spigset, O; Backstrom, T;
Indirizzi:
Umea Univ Hosp, Dept Clin Sci Obstet & Gynecol, S-90185 Umea, Sweden Umea Univ Hosp Umea Sweden S-90185 bstet & Gynecol, S-90185 Umea, Sweden Umea Univ Hosp, Dept Psychiat, S-90185 Umea, Sweden Umea Univ Hosp Umea Sweden S-90185 , Dept Psychiat, S-90185 Umea, Sweden Umea Univ Hosp, Dept Clin Neurosci & Pharmacol, S-90185 Umea, Sweden Umea Univ Hosp Umea Sweden S-90185 sci & Pharmacol, S-90185 Umea, Sweden Reg & Univ Hosp Trondheim, Dept Clin Pharmacol, Trondheim, Norway Reg & Univ Hosp Trondheim Trondheim Norway Pharmacol, Trondheim, Norway
Titolo Testata:
OBSTETRICS AND GYNECOLOGY
fascicolo: 3, volume: 98, anno: 2001,
pagine: 450 - 457
SICI:
0029-7844(200109)98:3<450:IOPHRT>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
H-3 PAROXETINE BINDING; SURGICALLY MENOPAUSAL WOMEN; PREMENSTRUAL-SYNDROME; ESTROGEN REPLACEMENT; IMIPRAMINE BINDING; AFFECTIVE-DISORDER; BLOOD-PLATELETS; DEPRESSION; ESTRADIOL; BRAIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
45
Recensione:
Indirizzi per estratti:
Indirizzo: Wihlback, AC Umea Univ Hosp, Dept Clin Sci Obstet & Gynecol, S-90185 Umea,Sweden Umea Univ Hosp Umea Sweden S-90185 ol, S-90185 Umea, Sweden
Citazione:
A.C. Wihlback et al., "Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and seroton(2A) receptor binding", OBSTET GYN, 98(3), 2001, pp. 450-457

Abstract

OBJECTIVE: To examine whether binding of [H-3]-paroxetine to the platelet serotonin transporter or binding of [H-3]lysergic acid diethylamide (LSD) to the platelet 5-HT2A receptor are influenced by postmenopausal estrogen/progestogen treatment. METHODS: Twenty-three postmenopausal women with climacteric symptoms completed this double-blind, randomized, crossover study. The women received 2 mg of estradiol continuously during four 28-day cycles. In the last 14 days of each cycle, 10 mg of medroxyprogesterone acetate, I mg of norethindrone acetate, or placebo was given. Before treatment, as well as once during thelast week of each treatment, blood samples were collected for analysis of [H-3]LSD and [H-3]paroxetine binding. The power of the study setup was 81%. The study had an effect size of 0.36, corresponding to the ability to detect a 15% difference in [H-3]paroxetine and [H-3]LSD binding between treatments with alpha = .05 and beta = .20, based on a previously reported standard deviation within cells of 20% of the mean binding values. RESULTS: The number of platelet receptors (B-max), or the affinity of the radioligand to the receptor (K-d), for [H-3]paroxetine binding did not change during estrogen or estrogen-progestogen treatment, nor did B-max or K-d for [H-3]LSD binding change during the different treatments. However, in a subgroup of depressed patients, the decrease in B-max for [H-3]LSD binding during treatment was significantly more pronounced than in the nondepressedsubgroup (P < .05). CONCLUSION: Estrogen treatment with or without the addition of progestogendoes not affect binding to the serotonin transporter or to die serotonergic 5-HT2A receptor in healthy postmenopausal women. (C) 2001 by the AmericanCollege of Obstetricians and Gynecologists.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/20 alle ore 00:56:08